Correction: Mineralocorticoid receptor (MR) antagonist eplerenone and MR modulator balcinrenone prevent renal extracellular matrix remodeling and inflammation via the MR/proteoglycan/TLR4 pathway.
出版信息
Clin Sci (Lond). 2024 Oct 16;138(20):1285. doi: 10.1042/CS-2024-0302_COR.
Abstract
摘要
相似文献
1
Correction: Mineralocorticoid receptor (MR) antagonist eplerenone and MR modulator balcinrenone prevent renal extracellular matrix remodeling and inflammation via the MR/proteoglycan/TLR4 pathway.更正：盐皮质激素受体（MR）拮抗剂依普利酮和MR调节剂巴尔西雷酮通过MR/蛋白聚糖/TLR4途径预防肾细胞外基质重塑和炎症。
Clin Sci (Lond). 2024 Oct 16;138(20):1285. doi: 10.1042/CS-2024-0302_COR.
2
Mineralocorticoid receptor (MR) antagonist eplerenone and MR modulator balcinrenone prevent renal extracellular matrix remodeling and inflammation via the MR/proteoglycan/TLR4 pathway.盐皮质激素受体（MR）拮抗剂依普利酮和MR调节剂巴尔西雷酮通过MR/蛋白聚糖/TLR4途径预防肾脏细胞外基质重塑和炎症。
Clin Sci (Lond). 2024 Aug 21;138(16):1025-1038. doi: 10.1042/CS20240302.
3
Biglycan Is a Novel Mineralocorticoid Receptor Target Involved in Aldosterone/Salt-Induced Glomerular Injury.聚糖蛋白聚糖是一种新型的盐皮质激素受体靶标，参与醛固酮/盐诱导的肾小球损伤。
Int J Mol Sci. 2022 Jun 15;23(12):6680. doi: 10.3390/ijms23126680.
4
Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion.AZD9977 的临床前药理学：一种新型的盐皮质激素受体调节剂，可将器官保护作用与电解质排泄作用分开。
PLoS One. 2018 Feb 23;13(2):e0193380. doi: 10.1371/journal.pone.0193380. eCollection 2018.
5
The Mineralocorticoid Receptor Antagonist Eplerenone Suppresses Interstitial Fibrosis in Subcutaneous Adipose Tissue in Patients With Type 2 Diabetes.醛固酮受体拮抗剂依普利酮可抑制 2 型糖尿病患者皮下脂肪组织的间质纤维化。
Diabetes. 2021 Jan;70(1):196-203. doi: 10.2337/db20-0394. Epub 2020 Oct 14.
6
Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: Results from the phase 2b MIRACLE trial.倍林达仑酮联合达格列净治疗心力衰竭合并慢性肾脏病患者：来自 2b 期 MIRACLE 试验的结果。
Eur J Heart Fail. 2024 Aug;26(8):1727-1735. doi: 10.1002/ejhf.3294. Epub 2024 May 23.
7
The selective mineralocorticoid receptor antagonist eplerenone prevents decompensation of the liver in cirrhosis.选择性盐皮质激素受体拮抗剂依普利酮可预防肝硬化失代偿。
Br J Pharmacol. 2018 Jul;175(14):2956-2967. doi: 10.1111/bph.14341. Epub 2018 Jun 7.
8
Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms.醛固酮、盐皮质激素受体激活与慢性肾脏病：不断演变的治疗模式述评。
Am J Kidney Dis. 2022 Nov;80(5):658-666. doi: 10.1053/j.ajkd.2022.04.016. Epub 2022 Sep 1.
9
Blood pressure variability activates cardiac mineralocorticoid receptor and induces cardiac remodeling in hypertensive rats.血压变异性激活心脏盐皮质激素受体，导致高血压大鼠心脏重构。
Circ J. 2013;77(6):1474-81. doi: 10.1253/circj.cj-12-1253. Epub 2013 Mar 7.
10
Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - New perspectives for combination therapy.非甾体类盐皮质激素受体拮抗剂治疗心血管和肾脏疾病-联合治疗的新视角。
Pharmacol Res. 2021 Oct;172:105859. doi: 10.1016/j.phrs.2021.105859. Epub 2021 Aug 28.
Zotero 插件